Rational design of LEDGINs as first allosteric integrase inhibitors for the treatment of HIV infection

Drug Discovery Today: Technologies

Volumn 10, Issue 4, 2013, Pages

  Desimmie, Belete A ^a   Demeulemeester, Jonas ^a   Christ, Frauke ^a   Debyser, Zeger ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; LENS EPITHELIUM DERIVED GROWTH FACTOR; PROTEIN P75; RALTEGRAVIR;

ALLOSTERISM; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATIONAL TRANSITION; DRUG DESIGN; HIGH THROUGHPUT SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSURVEILLANCE; NONHUMAN; PHARMACOPHORE; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; DRUG DESIGN; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; TRANSCRIPTION FACTORS;

EID: 84886234190     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.10.002     Document Type: Review

References (38)

1. T. Berg Modulation of protein-protein interactions with small organic molecules Angew. Chem. 42 2003 2462 2481
2. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009
3. M.R. Arkin, and J.A. Wells Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nat. Rev. Drug Discov. 3 2004 301 317
4. S. Jager Global landscape of HIV-human protein complexes Nature 481 2012 365 370
5. F. Christ Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication Nat. Chem. Biol. 6 2010 442 448
6. UNAIDS, Report on the global AIDS epidemic. Geneva, UNAIDS, 2010 (http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008, accessed 29 October 2011)
7. A. Lafeuillade Investigating cellular antiretroviral resistance: preliminary results of the ICARE study 3rd IAS Conference on HIV Pathogenesis and Treatment Rio de Janeiro, 24-27 July 2005 (abstract WeOa0201)
8. A. Lafeuillade Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations HIV Clin. Trials 3 2002 27 35
9. S. Moir Pathogenic mechanisms of HIV disease Annu. Rev. Pathol. 6 2011 223 248
10. J. Cohen HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts Science 334 2011 1614
11. A.L. Brass Identification of host proteins required for HIV infection through a functional genomic screen Science 319 2008 921 926
12. R. König Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication Cell 135 2008 49 60
13. L. Houzet, and K.T. Jeang Genome-wide screening using RNA interference to study host factors in viral replication and pathogenesis Exp. Biol. Med. 236 2011 962 967
14. P. Dorr Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 49 2005 4721 4732
15. S. Sayana, and H. Khanlou Maraviroc: a new CCR5 antagonist Expert Rev. Anti Infect. Ther. 7 2009 9 19
16. A.P. Rice, and R.E. Sutton Targeting protein-protein interactions for HIV therapeutics Future HIV Ther. 1 2007 369 385
17. P. Cherepanov HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells J. Biol. Chem. 278 2003 372 381
18. F.D. Bushman Retroviral DNA integration directed by HIV integration protein in vitro Science 249 1990 1555 1558
19. G.N. Maertens The mechanism of retroviral integration from X-ray structures of its key intermediates Nature 468 2010 326 329
20. P. Cherepanov Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75 Proc. Natl. Acad. Sci. U. S. A. 102 2005 17308 17313
21. S. Hare, and P. Cherepanov The interaction between lentiviral integrase and LEDGF: structural and functional insights Viruses 1 2009 780 801
22. K. Busschots In search of small molecules blocking interactions between HIV proteins and intracellular cofactors Mol. BioSyst. 5 2009 21 31
23. A. Ciuffi A role for LEDGF/p75 in targeting HIV DNA integration Nat. Med. 11 2005 1287 1289
24. M.K. Lewinski Retroviral DNA integration: viral and cellular determinants of target-site selection PLoS Pathog. 2 2006 e60
25. G.P. Wang HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications Genome Res. 17 2007 1186 1194
26. M. Llano An essential role for LEDGF/p75 in HIV integration Science 314 2006 461 464
27. H.M. Marshall Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting PLoS One 2 2007 e1340
28. J. De Rijck Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication J. Virol. 80 2006 11498 11509
29. A. Hombrouck Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV PLoS Pathog. 3 2007 e47
30. L. Vandekerckhove Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus J. Virol. 80 2006 1886 1896
31. L.Q. Al-Mawsawi Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis FEBS Lett. 582 2008 1425 1430
32. L. Du D77: one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75 Biochem. Biophys. Res. Commun. 375 2008 139 144
33. L. De Luca Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75 ChemMedChem 4 2009 1311 1316
34. Y. Hou Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay J. Biomol. Screen. 13 2008 406 414
35. S. Maignan Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases J. Mol. Biol. 282 1998 359 368
36. V. Molteni Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain Acta Crystallogr. D: Biol. Crystallogr. 57 Pt 4 2001 536 544
37. K. Bartholomeeusen Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75 J. Mol. Biol. 372 2007 407 421
38. D.J. Hazuda Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells Science 287 2000 646 650